Aurobindo Pharma Limited has informed the Exchange about receipt of approval for Dazublys biosimilar from UK s MHRA by CuraTeQ Biologics

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.9%Reaction day

₹1067.00

prior close

₹1057.20

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.5%-0.4% vs market

Pharmaceuticals peers, median of 150sector-1.5%-0.3% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.4

15m

-0.4

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.9-1.5-0.4-1.5-0.3

Next day

-3.5-2.6-0.8-2.0-1.4

-3.7-3.2-0.6-2.3-1.5

-3.8-1.5-2.3-1.4-2.4

-4.4-1.3-3.1-1.3-3.1

-3.0-0.7-2.3-0.5-2.5

-1.8-1.2-0.6-0.8-1.0

15d

+2.7+1.9+0.8-0.1+2.7

+2.2-2.2+4.4-3.6+5.8

+2.4+3.0-0.5-3.2+5.6

+15.8+4.6+11.2-5.3+21.1

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma's wholly-owned step-down subsidiary CuraTeQ Biologics has received marketing authorization from the UK's MHRA for Dazublys, its trastuzumab biosimilar used in breast cancer treatment. This is CuraTeQ's fourth biosimilar approval from MHRA, following Bevqolva (December 2024), Zefylti (May 2025), and Dyrupeg (June 2025). Dazublys had already received EU approval in July 2025, and three of the four biosimilars are now also approved in the European Union. The approval strengthens Aurobindo's biosimilars portfolio in key regulated markets.

Likely market impact

Positive for Aurobindo Pharma as it expands the company's biosimilar footprint in the UK and Europe, a high-value regulated market that can contribute meaningfully to future revenue from its biologics business.